GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tanvex BioPharma Inc (TPE:6541) » Definitions » Selling, General, & Admin. Expense

Tanvex BioPharma (TPE:6541) Selling, General, & Admin. Expense : NT$358.45 Mil (TTM As of Mar. 2025)


View and export this data going back to 2015. Start your Free Trial

What is Tanvex BioPharma Selling, General, & Admin. Expense?

Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. Tanvex BioPharma's selling, general, & admin. expense for the three months ended in Mar. 2025 was NT$110.75 Mil. Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Mar. 2025 was NT$358.45 Mil.


Tanvex BioPharma Selling, General, & Admin. Expense Historical Data

The historical data trend for Tanvex BioPharma's Selling, General, & Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tanvex BioPharma Selling, General, & Admin. Expense Chart

Tanvex BioPharma Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Selling, General, & Admin. Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 239.12 219.21 234.74 453.71 306.52

Tanvex BioPharma Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Selling, General, & Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 58.82 85.60 71.52 90.58 110.75

Competitive Comparison of Tanvex BioPharma's Selling, General, & Admin. Expense

For the Biotechnology subindustry, Tanvex BioPharma's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tanvex BioPharma's Selling, General, & Admin. Expense Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tanvex BioPharma's Selling, General, & Admin. Expense distribution charts can be found below:

* The bar in red indicates where Tanvex BioPharma's Selling, General, & Admin. Expense falls into.


;
;

Tanvex BioPharma Selling, General, & Admin. Expense Calculation

Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.

Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$358.45 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Tanvex BioPharma  (TPE:6541) Selling, General, & Admin. Expense Explanation

An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.

Warren Buffett likes companies with consistent SGA as the percentage of gross profit.

Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.

If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.


Tanvex BioPharma Selling, General, & Admin. Expense Related Terms

Thank you for viewing the detailed overview of Tanvex BioPharma's Selling, General, & Admin. Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Tanvex BioPharma Business Description

Industry
Traded in Other Exchanges
N/A
Address
No. 376, Ren\'ai Road, Section 4, 13th Floor-1, Da\'an District, Taipei, TWN, 106
Tanvex BioPharma Inc is a biopharmaceutical company. It is engaged in the research, development, manufacture, and sale of biosimilar products and contract development and manufacturing of biological medicine. The company's products are used to cure diseases such as Neutropenia, Breast Cancer, Metastatic Colorectal Cancer, and others. Geographically, the company generates a majority of its revenue from Taiwan and the rest from the United States.

Tanvex BioPharma Headlines

No Headlines